Author: admin

CCRM and CCRM Nordic AB have announced a strategic collaboration with IonQ, a key player in quantum computing technologies, designed to drive innovation at the nexus of advanced therapies and quantum computing. The partnership includes an initial investment commitment by IonQ to fuel joint initiatives across the global network of emerging CCRM hubs. The collaboration will focus on identifying and developing significant, high-impact use cases where quantum computing can transform the development, delivery and scalability of advanced therapies, according to officials at both companies. By bringing together CCRM’s expertise in next-generation therapeutic innovation and IonQ’s leadership in cutting-edge quantum computational…

Researchers cultured organoids of two primary bone marrow cell types in a 3D scaffold to create an accurate model of the endosteal niche.Image credit:Andrés García-García, University of Basel, Department of BiomedicineThe bone marrow serves as the main site of hematopoiesis in humans, giving rise to red and white blood cells. This space is highly organized into distinct regions, or niches, that perform different functions. One of these, the endosteal niche, lies closest to the bone and consists of bone-producing cells called osteoblasts, vascular cells, and hematopoietic stem cells. In mice, researchers have shown that this niche is often where blood…

As the number of antibiotic-resistant infections continues to rise, scientists are looking to bacteriophages (“phages”), viruses that infect bacteria, as an approach to tackling antibiotic resistance. A new study by researchers at the Hebrew University of Jerusalem has revealed how bacteriophages use a tiny piece of genetic material to hijack bacterial cells and make more copies of themselves. Focusing on infection of Escherichia coli by phage lambda, a bacteriophage that scientists have been studying for decades, research lead Sahar Melamed, PhD, and colleagues identified a virus-encoded small RNA molecule (sRNA) called phage replication enhancer sRNA (PreS) that acts like a…

Zealand Pharma partners Shanghai-based OTR Therapeutics in discovery deal focused on obesity and metabolic disease. Danish biotech Zealand Pharma has signed a discovery and development agreement with Shanghai-based OTR Therapeutics, committing at least $20 million upfront to identify new drug targets for metabolic diseases. The collaboration could expand to $30 million in upfront payments under certain conditions, with OTR also eligible for up to $2.5 billion in development and commercial milestones, plus tiered royalties on future sales. Under the terms, OTR will apply its discovery platform to identify multiple novel metabolic targets and advance them through preclinical development. Zealand is…

Credit: Svetlana Orusova / iStock / Getty Images Plus Earlier this month, Prime Medicine researchers hit a precision gene editing milestone when they published a peer-reviewed article reporting the first demonstration of prime editing to treat human patients. In this study, two patients with chronic granulomatous disease (CGD) were treated with PM359, an autologous hematopoietic stem-cell (HSC) therapy that aims to correct a disease-causing mutation with prime editing to restore immune function without double-strand DNA breaks or donor transplantation. The results have been promising, as both patients remained free of new CGD-related complications during the first few months of follow-up.…

From fleeting shower thoughts to questions that just won’t leave one’s mind, dive into the scientific curiosities that captivate readers. Researchers investigate why certain human traits exist—such as what determines earwax types, what drives variations in sweat and body odor, and why humans have long scalp hair. They also dig into age-old mysteries like how dinosaurs grew to such massive sizes, as well as modern questions about the benefits and risks of trends like cold-water plunges. Using genetics, molecular techniques, computer simulations, and more, researchers are uncovering new insights into evolution, physiology, and human activity. By unraveling the science behind…

Prof David Allison on healthspan, nutrition and how we can overcome the challenge of testing the efficacy of longevity interventions. Hevolution Foundation recently released the second edition of its Global Healthspan Report, offering one of the most comprehensive assessments to date of the science, technology, investments and policies shaping how long people live in good health. Drawing on global surveys, investment analyses, expert interviews and an extensive review of emerging research, the 2025 report shifts the conversation from defining healthspan to accelerating its progress. Longevity.Technology: The new Global Healthspan Report examines where meaningful advances have already been made and what…

3D structure representation of the CD38 extracellular domain in complex with isatuximab and daratumumab [Rosalba Lepore, University of Basel] Natural genetic differences can impact the ability of monoclonal antibody (mAbs) therapies to bind to their target proteins, research suggests. The findings, in Science Translational Medicine, suggest these variations should therefore be considered in the design of drugs and their clinical use. They could also impact how the therapies are tested in clinical trials and tailored for individual patients during treatment. For almost every antibody analyzed, the researchers found protein variants either within or near the antibody-antigen interface. In a significant…

Source: Juan Gaertner/Science Photo Library Cancer immunotherapy transforms a patient’s immune cells into a “search‑and‑destroy” force against tumors. But many cancers learn to camouflage themselves from dendritic cells—the immune system’s scouts—making them harder to detect and target. Dendritic cells normally collect tumor antigens and present them to T cells, which then attack cancer cells. Clinicians have tried to overcome tumor evasion by harvesting dendritic cells from patients, loading them with tumor antigens in the lab, and reinfusing them in an effort to train dendritic cells to better identify the tumor. Yet this approach is limited: lab‑grown dendritic cells often lack…

Credit: peterschreiber.media/Getty Images A new study has found that the Brain Care Score (BCS), a tool developed at Mass General Brigham, can accurately predict stroke risk across racial groups in the U.S. Results published today in Neurology show that behavioral changes to improve BCS scores could particularly improve stroke prevention among Black individuals.  “Black adults in the United States face a two- to threefold higher risk of stroke compared to White adults,” said Sanjula Dhillon Singh, MD, PhD, principal investigator in the Brain Care Labs at Massachusetts General Hospital and Harvard Medical School. “Our findings show that the Brain Care Score…